Hepatic injury during doxorubicin therapy

Area of Science:

• Oncology
• Hepatology
• Pharmacology

Background:

• Acute lymphoblastic leukemia (ALL) is a significant hematologic malignancy.
• Doxorubicin hydrochloride is a common chemotherapeutic agent used in ALL treatment.
• Potential adverse effects of chemotherapy require thorough investigation.

Purpose of the Study:

• To investigate the potential link between doxorubicin hydrochloride therapy and liver dysfunction in ALL patients.
• To identify doxorubicin hydrochloride as a potential cause of hepatic dysfunction, ruling out other etiologies.

Main Methods:

• Case series involving six patients diagnosed with acute lymphoblastic leukemia.
• Clinical observation and laboratory assessment to evaluate liver function.
• Exclusion of alternative causes for liver dysfunction, including infection, hepatitis, posttransfusion reactions, and leukemic infiltration.

Main Results:

• Six patients undergoing doxorubicin hydrochloride therapy exhibited signs of liver dysfunction.
• A strong temporal correlation was observed between doxorubicin administration and the onset of hepatic dysfunction.
• Other potential causes of liver injury were systematically excluded.

Conclusions:

• Doxorubicin hydrochloride therapy is associated with liver dysfunction in acute lymphoblastic leukemia patients.
• The observed hepatic dysfunction may represent an idiosyncratic drug reaction.
• Doxorubicin hydrochloride should be recognized for its potential liver toxicity.